CN117624334A - Preparation method of De-valley insulin crystal - Google Patents

Abstract

The invention provides a preparation method of De-Glutamine crystal. The method specifically comprises the following steps: firstly, providing a crystallization liquid composed of insulin deltoid, phenolic substances, salt substances, a pH regulator and a solvent, wherein the insulin deltoid is added into the crystallization liquid in the form of a chromatographic collection liquid containing the insulin deltoid and acetonitrile; and then crystallizing to obtain the insulin deltoid crystal. According to the method, the chromatographic collection liquid containing acetonitrile in the preparation process of the insulin deltoid can be used as a raw material for direct crystallization, histidine or other proteins are not required to be added in the crystallization process, so that the production process of the insulin deltoid crystal is simpler, the cost is lower, and the obtained insulin deltoid crystal has the advantages of small sedimentation volume, stable crystal, easiness in drying and the like.

Description

Preparation method of De-valley insulin crystal

Technical Field

The invention relates to the field of biological pharmacy, in particular to a preparation method of a human insulin analogue, namely Degu insulin crystal.

Background

Diabetes is a major disease that threatens human health worldwide. Along with the improvement of the living standard of people, the change of life style and the acceleration of the aging process, the prevalence rate of diabetes mellitus is rapidly increased. The acute and chronic complications of diabetes, especially the chronic complications involve a plurality of organs, have high disability and mortality, seriously affect the physical and mental health of patients, and bring heavy burden to individuals, families and society.

Insulin therapy is an important means of treating diabetes and allowing good control of blood glucose. In the last 70 th century, recombinant human membrane island elements were developed by genetic engineering techniques. Later, in order to obtain drugs with different action time profiles, such as fast-acting or long-acting, a series of insulin analogues have been developed successively. Insulin analogues known at present are fast acting insulin lispro, insulin aspart, long acting insulin glargine, insulin detete and insulin deglutition.

The Degu insulin is a novel ultra-long acting insulin, and the molecular structure of the Degu insulin is characterized in that the threonine at position 30 of the B chain is removed from human insulin, and a 16C fatty diacid side chain is connected to a lysine residue at position B29 through 1 glutamic acid molecule. The pharmacodynamic curve of the insulin deltoid has small fluctuation and can be kept stable within 24 hours.

Crystallization is an important link in the production of insulin-like substance crude drugs. The crystallized Degu insulin crystal has the characteristics of large particles, quick sedimentation, easiness in supernatant separation and short freeze drying time, and is more suitable for industrial production; and the bulk drug in solid crystal form has better product stability compared with amorphous solid powder.

CN 104892749A patent provides a crystallization method of insulin diglucoside. The preparation method of the insulin deltoid crystal in the patent comprises the following steps: (1) Preparing a crystallization liquid containing 0.05-0.27M histidine, 1-8 g/L insulin deluge, 8-15% organic solvent by volume percentage, 0.2-0.5% phenolic substance by mass and volume percentage and 0.3-2.4M salt; (2) Adjusting the pH value of the crystallization liquid to 6.5-8, adding zinc ions, wherein the dosage of the zinc ions is 2-15 based on the molar ratio of the zinc ions to the insulin deluge: 3, counting; crystallizing; (3) Then standing and crystallizing at the temperature of 2-8 ℃ to obtain the stable insulin deltoid crystal. The patent emphasizes in particular that histidine is one of the key factors in the crystallization of insulin delbrueck: under the condition of no histidine, the insulin deltoid can only form fine crystal particles, has slow solid-liquid separation and is not suitable for commercial production.

Therefore, the technical need is to invent a preparation method of Degu insulin crystals with high recovery rate, convenient operation, low cost and high crystal stability.

Disclosure of Invention

The invention aims to provide the Degu insulin crystallization method which has high recovery rate, convenient operation, low cost and high crystal stability.

In a first aspect of the present invention, there is provided a method for preparing a crystal of insulin deluge, the method comprising the steps of:

(1) Providing a crystallization liquid, wherein the crystallization liquid consists of insulin deluge, salt substances, phenolic substances, zinc salts, a pH regulator and a solvent;

the insulin diglucoside is added into the crystallization liquid in the form of a chromatographic collection liquid containing the insulin diglucoside; acetonitrile is included in the chromatographic collection liquid of the insulin diglucoside;

(2) Crystallizing to obtain the insulin diglucoside crystal.

It should be understood that the steps of the preparation method of the insulin diglucent crystal of the present invention are not limited to the above steps, and other additional steps may be included after the step (2) between the steps (1) and (2) before the step (1), and are all within the scope of the present invention. In another preferred embodiment, the insulin diglucoside chromatographic collection liquid is eluted through a reverse phase chromatographic column.

In another preferred embodiment, the crystallization liquid is formulated at 15-28 ℃, preferably 18-25 ℃.

In another preferred embodiment, the collection liquid by chromatography of insulin diglucoside is a collection liquid purified from the process of preparing insulin diglucoside.

In another preferred embodiment, the collection liquid of the insulin diglucoside chromatography comprises insulin diglucoside, acetonitrile, ammonium acetate and a small amount of impurities.

In another preferred embodiment, the collection liquid of the insulin diglucoside chromatography consists essentially of insulin diglucoside, acetonitrile, ammonium acetate and a small amount of impurities.

In another preferred embodiment, the insulin diglucoside chromatographic collection solution comprises one or more characteristics selected from the group consisting of:

(a) The concentration of the Degu insulin is 0.5-15 mg/mL, preferably 2-10 mg/mL;

(b) The volume fraction of acetonitrile is 10% to 40%, preferably 22% to 35%, more preferably 24% to 30%.

In another preferred embodiment, the concentration of insulin in the collected liquid of insulin in de-glulisine chromatography is 0.5-15 mg/mL, preferably 2-10mg/mL.

In another preferred embodiment, the content of ammonium acetate in the insulin diglucoside chromatographic collection solution is 3.5 to 4.0mol/L.

In another preferred embodiment, the step (s 1) further includes: concentrating or diluting the insulin diglucoside chromatographic collection liquid, and adding the concentrated or diluted insulin diglucoside chromatographic collection liquid into the crystallization liquid.

In another preferred embodiment, the crystallization liquid comprises one or more characteristics selected from the group consisting of:

(a) The phenolic substance is selected from the group consisting of: phenol, o-cresol, m-cresol, p-cresol, m-ethylphenol, or combinations thereof, preferably phenol;

(b) The salt substance is selected from the following group: sodium chloride, potassium chloride, ammonium acetate, sodium acetate, ammonium citrate, sodium citrate, or a combination thereof, preferably sodium chloride;

(c) The zinc salt is selected from the group consisting of: zinc chloride, zinc bromide, zinc iodide, zinc acetate, zinc oxide, zinc sulfate, or a combination thereof, preferably an inorganic zinc salt, more preferably zinc chloride;

(d) The pH regulator is an alkaline regulator or an acidic regulator, wherein the alkaline regulator is selected from sodium hydroxide, potassium hydroxide and ammonia water, and sodium hydroxide is preferred; the acidity regulator is selected from hydrochloric acid, acetic acid, citric acid, preferably hydrochloric acid;

(e) The pH of the crystallization liquid is 6.6-8, preferably 6.6-7.5, more preferably 6.8-7.2, for example 6.8, 7.0, 7.05, 7.1, 7.15;

(f) The solvent includes water and acetonitrile.

In another preferred example, the crystallization liquid consists of insulin deltoid or a solution thereof, a salt substance solution, a phenol substance solution, a supplementary solvent, a pH regulator solution and a zinc salt solution.

In another preferred example, the preparation process of the crystallization liquid is as follows: adding salt substance solution, phenol substance solution, supplementary solvent, pH regulator solution and zinc salt solution into insulin deltoid or its solution to obtain crystal liquid.

In another preferred embodiment, the salt solution includes a salt and a first solvent.

In another preferred embodiment, the first solvent is water.

In another preferred embodiment, the concentration of the salt substance in the salt substance solution is 1 to 4mol/L, preferably 2 to 4mol/L, for example 3mol/L, 4mol/L.

In another preferred embodiment, the phenolics solution comprises phenolics and a second solvent.

In another preferred embodiment, the second solvent is selected from the group consisting of: acetonitrile, methanol, ethanol, isopropanol, or a combination thereof.

In another preferred embodiment, the concentration of the phenolics in the phenolics solution is in the range of 30% to 80% (g/ml), preferably 50% to 60% (g/ml).

In another preferred embodiment, the supplemental solvents are water and acetonitrile.

In another preferred embodiment, when the insulin is added to the crystallization as a chromatographic collection solution, no additional acetonitrile is required.

In another preferred embodiment, when the insulin is added to the crystallization liquid as a chromatographic collection liquid, the supplemental solvent is water.

In another preferred embodiment, the pH adjustor solution comprises a pH adjustor and a third solvent.

In another preferred embodiment, the third solvent is water.

In another preferred embodiment, the zinc salt solution comprises a zinc salt and a fourth solvent.

In another preferred embodiment, the fourth solvent is water.

In another preferred embodiment, the crystallization liquid comprises one or more characteristics selected from the group consisting of:

(a) The concentration of the insulin digluconate in the crystallization liquid is 2-8 g/L, preferably 2.5-4 g/L, such as 3g/L, 3.4g/L, 3.6g/L;

(b) The volume fraction of acetonitrile in the crystallization liquid is 10% -20%, preferably 10% -15%, for example 12%;

(c) The phenolic substance accounts for 0.05 to 1.0 percent, preferably 0.05 to 0.5 percent, more preferably 0.1 to 0.5 percent, such as 0.1 percent and 0.2 percent of the mass volume of the crystallization liquid;

(d) The concentration of the salt substance in the crystallization liquid is 0.5 to 1.5mol/L, preferably 0.8 to 1.2mol/L, for example 1mol/L;

(e) The molar ratio of the zinc salt to the insulin deltoid is (0.5-5): 1, preferably (1-3): 1, more preferably (1.5-2): 1, a step of;

(f) The pH of the crystallization liquid is 6.6-8, preferably 6.6-7.5.

In another preferred embodiment, the crystallization is carried out at a temperature of 0 to 10 ℃, preferably 2 to 8 ℃.

In another preferred embodiment, the crystallization is stirred crystallization and/or stationary crystallization, preferably stationary crystallization.

In another preferred embodiment, the time for the crystallization is 4 to 24 hours, preferably 6 to 20 hours, more preferably 12 to 20 hours.

In another preferred embodiment, the method comprises: preparing a crystallization liquid at 15-28 ℃, wherein the crystallization liquid comprises 2-8 g/L of insulin deluge, 0.05-1.0% g/ml of phenolic substances, 0.5-1.5 mol/L of salt substances, 10-20% (ml/ml) of organic solvent, and the molar ratio of zinc salt to insulin deluge (0.5-5): 1, a step of; regulating pH to 6.6-8, cooling to 2-8 deg.c, and crystallizing for 4-24 hr to obtain insulin crystal.

In another preferred embodiment, the method further comprises a post-treatment step, more preferably, the post-treatment step comprises a washing step. More preferably, the washing step is followed by a drying step.

In another preferred embodiment, the post-processing step includes: removing the supernatant of the crystallization liquid to obtain a deluge insulin crystal solution, adding a detergent, standing, pumping out the supernatant to obtain a deluge insulin crystal, and freeze-drying to obtain the deluge insulin bulk drug.

In another preferred embodiment, the detergent is water.

In another preferred example, the volume ratio of the insulin diglucoside crystal solution to the detergent is 1: (5-15), preferably 1: (7-12), more preferably 1:9.

In another preferred example, the washing step is to mix the insulin diglucoside crystal solution with a detergent, stand at 2-8 ℃ for 4 hours, and then withdraw the supernatant.

In another preferred embodiment, the number of washes in the washing step is 1, 2, 3, 4, preferably 3.

In another preferred embodiment, the freeze-drying time is 24 to 70 hours. Preferably, the freeze-drying time is 50-70h.

In a second aspect of the present invention there is provided a crystal of insulin de-glargine, preferably produced by the method disclosed in the first aspect, more preferably the crystal of insulin de-glargine is a rod-like crystal.

In another preferred embodiment, the insulin deltoid crystal has one or more characteristics selected from the group consisting of:

(i) The crystals have a burn residue content of less than 5%, preferably less than 3%, more preferably less than 2%;

(ii) The organic solvent residue of the crystals is less than 300ppm, preferably less than 100ppm, more preferably undetected;

(iii) The phenolic residue of the crystals is less than 2000ppm, more preferably less than 1000ppm;

(iv) The length of the rod-like crystal is 10 to 80. Mu.m, more preferably 30 to 40. Mu.m.

It is understood that within the scope of the present invention, the above-described technical features of the present invention and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. And are limited to a space, and are not described in detail herein.

Drawings

FIG. 1 is a schematic diagram of molecular structure of Deguinsulin.

FIG. 2 shows a photomicrograph of comparative example 1 at 500 Xmagnification of the crystal.

Fig. 3 shows a photomicrograph of comparative example 2 at 500 x magnification.

Fig. 4 shows a photomicrograph of comparative example 3 at 500 x magnification.

Fig. 5 shows a photomicrograph of comparative example 4 at 500 x magnification.

Fig. 6 shows a photomicrograph of example 2 at 500 x magnification.

FIG. 7 shows a photomicrograph of example 3 at 500 Xmagnification of the crystal.

Detailed Description

The present inventors have conducted extensive and intensive studies and have unexpectedly found a method for producing insulin deltoid crystals. The method directly uses the eluent in the preparation process of the insulin diglucoside as a raw material, the eluent does not need to be concentrated, precipitated and dissolved, the eluent containing impurities is crystallized into the rod-shaped crystals with regular shapes, and the recovery rate is extremely high (more than 98%). The crystallization method of the invention does not need to add expensive histidine and other raw materials, does not need to supplement acetonitrile, greatly reduces the cost, has simple and easy operation and high recovery rate, and can realize the large-scale production. The present invention has been completed on the basis of this finding.

De-glu insulin

The structure of the insulin deltoid in the present invention is shown in FIG. 1, and this structural modification allows it to exist stably in the preparation as a double hexamer with the aid of zinc ions, phenol, m-cresol, etc. After subcutaneous injection, the double hexamer aggregates itself to form a polyhexamethylene with rapid diffusion of phenols in the preparation, and slowly dissociates to release monomers during zinc ion dispersion, which are absorbed into blood circulation. The reversible combination of the side chain fatty acid and HSA further slows down the absorption and diffusion speeds of the medicine, thereby playing a long-acting hypoglycemic role.

Degu insulin chromatographic collection liquid

The chromatographic collection liquid of the insulin diglucoside is a purified intermediate in the process of preparing the insulin diglucoside, and does not need concentration, precipitation and redissolution.

Preferably, the collection liquid of the reverse phase chromatography of the insulin diglucoside contains the insulin diglucoside, acetonitrile, ammonium acetate and a small amount of impurities.

More preferably, the collection solution of insulin diglucoside by reverse phase chromatography is composed of insulin diglucoside, acetonitrile, ammonium acetate and a small amount of impurities.

In the delta insulin chromatographic collection liquid, the concentration of the delta insulin is 0.5-15 mg/mL, preferably 2-10mg/mL.

In the delta insulin chromatographic collection liquid, the volume fraction of acetonitrile is 10% -40%, preferably 22% -35%, more preferably 24% -30%.

In the insulin diglucoside chromatographic collection liquid, the concentration of ammonium acetate is 2-5mol/L, preferably 3.5-4.0 mol/L.

The crystallization method of the present invention

The invention provides a crystallization method, which comprises the following steps:

preparing a crystallization liquid at 15-28 ℃, wherein the crystallization liquid comprises 2-8 g/L of insulin deluge, 0.05-1.0% g/ml of phenolic substances, 0.5-1.5 mol/L of salt substances, 10-20% (ml/ml) of organic solvent, and the molar ratio of zinc salt to insulin deluge (0.5-5): 1, a step of; adjusting the pH value to 6.6-8, then cooling to 2-8 ℃ and crystallizing for 4-24 hours to obtain the insulin deluge crystal.

In the preparation stage of the crystallization liquid, the proper temperature is favorable for increasing the solubility of the insulin diglucoside, and the insulin diglucoside is not easy to form precipitate. The temperature of the crystallization liquid is 15-28 ℃, and the preferable temperature is 18-25 ℃.

The insulin deltoid can be prepared by chemical synthesis or biological synthesis. The concentration of the insulin diglucoside in the crystallization liquid is 2-8 g/L, and the preferable concentration is 2.5-4 g/L.

According to the fact that the insulin deltoid crystals are regular bodies formed by regular arrangement of insulin deltoid hexamers, the formation of the hexamers is a key stage, and phenols, buffer salts and salt substances play an important role in forming stable hexamers.

The phenolic substances in the crystallization liquid are phenol, o-cresol, m-cresol and p-cresol, and more preferably the phenolic substances are phenol; the concentration of the phenolic substance is 0.05 to 1.0% (g/ml), more preferably 0.1 to 0.5% (g/ml).

The salt substances are sodium chloride, potassium chloride, ammonium acetate, sodium acetate, ammonium citrate and sodium citrate, and more preferably sodium chloride; the concentration of the salt substance is 0.5 to 1.5mol/L, more preferably 0.8 to 1.2mol/L.

The organic solvent is one or a mixture of any two or three of acetonitrile, ethanol and isopropanol, and is more preferably acetonitrile; the volume fraction of the organic solvent is 10% -20% (ml/ml), and more preferably 10% -15% (ml/ml).

The pH is adjusted by using reagents known to those skilled in the art, preferably sodium hydroxide, potassium hydroxide, ammonia, hydrochloric acid, acetic acid, citric acid, more preferably sodium hydroxide and hydrochloric acid; the pH is 6.6-8, more preferably 6.6-7.5.

The zinc ions are added in the form of zinc salts; the zinc salt is as follows: zinc chloride, zinc acetate, zinc oxide, zinc bromide, zinc iodide, zinc sulfate, more preferably zinc chloride; the molar ratio of zinc ions to insulin deluge is (0.5-5): 1, more preferably the molar ratio is (1 to 3): 1.

under the conditions of low temperature and long time, small crystal nucleus can be gradually grown to form regular crystals which can be settled to the bottom of the crystallization liquid. The crystallization is carried out for 4 to 24 hours at a temperature of 2 to 8 ℃, and more preferably for 6 to 20 hours at a temperature of 2 to 8 ℃.

The sample source of the method is a reversed phase chromatography collection liquid containing insulin diglucoside. The preparation of the insulin deltoid crystal by the method has the great advantages that: the organic solvent used in the method is well connected with the process of fine purification of the insulin diglucoside (the fine purification is mostly acetonitrile used for reversed phase chromatography organic phase), and no organic solvent is specially added or removed. The Degu insulin crystal prepared by the invention has the advantages of high recovery rate, short sedimentation time and small volume.

The main advantages of the invention include:

1) The invention can prepare the insulin deluge crystal, and has high recovery rate (more than 98 percent); meanwhile, the insulin digallin crystal can be settled to the bottom of the crystallization liquid, and separation of the insulin digallin crystal and the solution can be achieved by pumping supernatant.

2) According to the preparation method of the Degu insulin crystal, histidine is not required to be added, so that the introduction of impurities is reduced; meanwhile, the use amount of zinc ions is low, which is beneficial to reducing the risk of exceeding the standard of zinc ions in the bulk drug.

3) The invention can directly use the finely purified collecting liquid as the initial solution of crystallization, which can be in seamless connection with the previous process, and does not need to add organic solvents such as ethanol, acetonitrile and the like in order to assist crystallization.

4) The deluge insulin crystal prepared by the method can meet the quality requirement of the deluge insulin bulk drug through washing and drying, has higher recovery rate, and is suitable for commercial production.

5) The deluge insulin crystal obtained by the method has the advantages of small sedimentation volume, stable crystal and more energy conservation, and is suitable for commercial production of the deluge insulin bulk drug.

The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental methods, in which specific conditions are not noted in the following examples, are generally conducted under conventional conditions or under conditions recommended by the manufacturer. Percentages and parts are weight percentages and parts unless otherwise indicated.

Comparative example 1

100mL of the reverse phase chromatography collection liquid was taken, acetonitrile 28% (mL/mL) and insulin diglucoside concentration 8.3mg/mL. To this was added 5.8g of histidine, 0.49g of phenol, 18.4g of sodium chloride, 103ml of purified water, the pH was adjusted to 7.02 with 0.5mol/L sodium hydroxide solution at a temperature of 21℃and 140. Mu.l of 1mol/L zinc chloride solution was added; crystallizing; then transferring to the environment of 2-8 ℃ for standing and crystallizing for 16 hours.

Results: HPLC detection of the crystalline supernatant has a insulin content of 0.52mg/ml and a crystallization recovery rate of 85%, which is not beneficial to commercial production. After being uniformly mixed, the mixture is subjected to microscopic examination, and the picture shows that the insulin crystal is polyhedral, but irregular. The crystal is shown in fig. 2.

Comparative example 2

A dry powder containing 0.52g of insulin deluge was taken, 43.3ml of a sodium chloride solution, 0.007ml of a 50% (g/ml) phenol ethanol solution, 20.8ml of an acetonitrile solution, 0.4ml of a 0.5mol/L sodium hydroxide solution, 109ml of purified water were sequentially added, the concentration of insulin deluge was controlled to 3.0g/L, naCl 1.0.0 mol/L, 0.2% (g/ml) phenol, and 12% (ml/ml) acetonitrile, and 0.26ml of a zinc chloride solution was added to obtain a final volume 173ml of a crystal solution, pH7.0. Standing and crystallizing for 19 hours at the temperature of 2-8 ℃.

Results: when De-glutamic acid powder was used as a raw material and acetonitrile solvent was added thereto, the content of De-glutamic acid in the supernatant liquid was measured by HPLC and found to be 0.38mg/ml, whereby the recovery rate of crystals was 87.3%. After being mixed uniformly, the mixture is subjected to microscopic examination, and the picture shows that the insulin diglucoside crystals are irregular and small, and only have partial rod-shaped crystals. The crystal is shown in fig. 3.

Example 1

An eluate containing insulin diglucoside was obtained according to the method disclosed in patent application No. 202010523798.3 for the subsequent crystallization process.

The solution containing insulin deluge (purity of insulin deluge 95%) was loaded onto a C8 reversed phase chromatography column by a pump, eluted with mobile phase A (5 mM ammonium acetate, water; pH 4.5) and mobile phase B (acetonitrile), and collected to obtain a chromatography collection solution containing insulin deluge and acetonitrile. The purity of the insulin diglucoside in the chromatographic collection liquid is more than 99.6%, the concentration of the insulin diglucoside is 2-10mg/ml, the content of acetonitrile is 24% -30% (ml/ml), and the concentration of ammonium acetate is 3.5-4.0 mol/L and a small amount of impurities.

Comparative example 3

60ml of the Degu insulin chromatography collection liquid prepared in example 1, which contained 29% (ml/ml) acetonitrile and 0.498g of Degu insulin, was taken, and 36.3ml of 4mol/L NaCl solution, 3.6g of histidine, 0.029ml of 50% (g/ml) phenol ethanol solution, 48ml of purified water, 0.3ml of 0.5mol/L sodium hydroxide solution, 0.16ml of 1mol/L zinc chloride solution, was added to control the final concentration of Degu insulin to 3.4mg/ml, naCl1.0mol/L, histidine 0.16mol/L, phenol 0.1%, acetonitrile 12%, zinc ion to Degu insulin molar ratio 2:1, the pH value was adjusted to 7.0 to obtain a crystal liquid having a final volume of 145 ml. Standing and crystallizing for 16 hours at the temperature of 2-8 ℃.

Results: when histidine was added to the system, HPLC was performed to detect that the insulin content of the crystal supernatant was 0.372mg/ml, and the recovery rate of crystals was 89.1%. And (3) after uniformly mixing, carrying out microscopic examination, and displaying that the insulin deltoid crystal is amorphous precipitate. The crystal is shown in fig. 4.

Comparative example 4

60ml of the Degu insulin chromatography collection liquid prepared in example 2, which contains 29% (ml/ml) acetonitrile and 0.498g of Degu insulin, was taken, 36.3ml of 4mol/L NaCl solution, 0.029ml of 50% (g/ml) phenol ethanol solution, 48ml of purified water, 0.3ml of 0.5mol/L sodium hydroxide solution, 0.16ml of 1mol/L zinc chloride solution were added, and the final concentration of Degu insulin was controlled to 3.4mg/ml, 1.0mol/L NaCl, 0.1% phenol, 12% acetonitrile, and a molar ratio of zinc ions to Degu insulin of 2:1, the pH value was adjusted to 7.0 to obtain a crystal liquid having a final volume of 145 ml. Shaking the crystal for 18 hours at 2-8 ℃ by shaking the crystal table at 200 revolutions per minute.

Results: when the crystals were shaken using a shaker, the HPLC analysis of the supernatant of the crystals showed a insulin content of 0.31mg/ml and a recovery rate of the crystals of 90.9%. And (5) carrying out microscopic examination after uniformly mixing, displaying pictures, and enabling the insulin deltoid crystals to be irregular. The crystal is shown in fig. 5.

Example 2

60ml of the Degu insulin chromatography collection liquid prepared in example 1, which contains 29% (ml/ml) acetonitrile and 0.498g of Degu insulin, was taken, 36.3ml of 4mol/L NaCl solution, 0.029ml of 50% (g/ml) phenol ethanol solution, 48ml of purified water, 0.3ml of 0.5mol/L sodium hydroxide solution, 0.16ml of 1mol/L zinc chloride solution were added, and the final concentration of Degu insulin was controlled to 3.4mg/ml, 1.0mol/L NaCl, 0.1% phenol, 12% acetonitrile, and a molar ratio of zinc ions to Degu insulin of 2:1, the pH value was adjusted to 7.0 to obtain a crystal liquid having a final volume of 145 ml. Standing and crystallizing for 16 hours at the temperature of 2-8 ℃.

Results: HPLC detection of the crystalline supernatant had a insulin content of 0.06mg/ml and a crystalline recovery of 98.2%. And after being uniformly mixed, the mixture is subjected to microscopic examination, and the picture shows that the insulin crystal is a regular rod-shaped crystal. The crystal is shown in fig. 6.

Example 3

1900ml of the Degu insulin chromatography collection liquid prepared in example 1, which contains 28.5% (ml/ml) acetonitrile and 16.3g of Degu insulin, was taken, 1128ml of 4mol/L NaCl solution, 0.9ml of 50% (g/ml) phenol ethanol solution, 1470ml of purified water, 9.3ml of 0.5mol/L sodium hydroxide solution, 4ml of 1mol/L zinc chloride solution were added, and the final concentration of Degu insulin was controlled to 3.6mg/ml, 1.0mol/L NaCl, 0.1% phenol, 12% acetonitrile, and the molar ratio of zinc ions to Degu insulin was 1.5:1, the pH value is regulated to 6.7, and a crystallization liquid with a final volume of 4512ml is obtained. Standing and crystallizing for 14 hours at the temperature of 2-8 ℃.

Results: HPLC detection of the insulin content of the supernatant of the crystallization is 0.07mg/ml, and the crystallization recovery rate is 98.1%. After being mixed uniformly, the mixture is subjected to microscopic examination, and the picture shows that the insulin crystal is a regular rod-shaped crystal with the crystal length of 30-40 microns. The crystal is shown in fig. 7.

EXAMPLE 4 filtration and washing

The supernatant of the crystalline liquid in example 3 was withdrawn to obtain 105ml of a solution containing insulin diglucoside crystals, 4407ml of the supernatant, and HPLC detection of the content of insulin diglucoside in the crystalline supernatant was 0.06mg/ml, losing 264mg insulin diglucoside;

adding 945ml of purified water solution into the concentrated solution containing the insulin deltoid crystal, standing for 4 hours at the temperature of 2-8 ℃, pumping out 945ml of supernatant, detecting the content of the insulin deltoid Gu Yi island by HPLC (high performance liquid chromatography) to obtain 56.7mg insulin deltoid;

then 945ml of purified water solution is added into the concentrated solution containing the crystals, the mixture is kept stand for 4 hours at the temperature of 2 to 8 ℃, 945ml of supernatant is pumped out, the content of the island of the De Gu Yi is detected by HPLC to be 0.07mg/ml, and 66.2mg of Degu insulin is lost;

then 945ml of purified water solution is added into the concentrated solution containing the crystals, the mixture is kept stand for 4 hours at the temperature of 2 to 8 ℃, 945ml of supernatant is pumped out, the content of the island of the De Gu Yi is detected to be 0.07mg/ml by HPLC, and 66.2mg of Degu insulin is lost.

Total loss of deglutition insulin: 264+56.7+66.2+66.2mg= 453.1mg, crystallization+wash recovery= (1-453.1/16300) ×100% =97.2%.

Example 5

The solution containing the insulin diglucoside crystals obtained in the third washing in example 4 was freeze-dried for 60 hours to obtain insulin diglucoside freeze-dried powder, and the detection result: 0.9% of the ignition residue (less than 6.0% required by ICH limit), 0.3% of zinc content, no acetonitrile residue detected, 972ppm of phenol residue (less than 5000ppm required by ICH limit), the length of the rod-like crystals being 30 to 40 μm.

The result shows that the crystal obtained by the method can control various reagent residues within the limit of the raw material medicine only by washing with purified water.

Discussion of the invention

The raw material of the deltoid insulin in the application does not need concentration, precipitation and redissolution, and can be directly added into the crystallization liquid in the form of chromatographic eluent, but the deltoid insulin crystal with extremely high recovery rate is obtained unexpectedly. The solvent in the crystallization method also contains acetonitrile, can be directly connected with the acetonitrile solvent in the chromatographic eluent in the process, and does not need to be supplemented with acetonitrile to assist crystallization.

In addition, the crystallization liquid system of the invention is very simple, does not contain expensive histidine reagent, and can obtain rod-shaped insulin deluge crystals with high yield and regular shape by using only the most common organic reagent.

In the prior art, most of the refined insulin deltoid powder is taken as a raw material, that is, the insulin deltoid can be applied to the crystallization liquid only by precipitation and redissolution of eluent, solvents such as acetonitrile, ethanol, isopropanol and the like are additionally added into the crystallization system, histidine is also added into the crystallization system to improve the size of crystal particles, and specific recovery rate is not reported.

All documents mentioned in this application are incorporated by reference as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the claims appended hereto.

Claims (10)

1. A method for preparing a crystal of insulin de-glu, comprising the steps of:

(1) Providing a crystallization liquid, wherein the crystallization liquid consists of insulin deluge, salt substances, phenolic substances, zinc salts, a pH regulator and a solvent;

the insulin diglucoside is added into the crystallization liquid in the form of a chromatographic collection liquid containing the insulin diglucoside; acetonitrile is included in the chromatographic collection liquid of the insulin diglucoside;

(2) Crystallizing to obtain the insulin diglucoside crystal.

2. The method of claim 1, wherein the collection fluid comprises insulin diglucoside, acetonitrile, ammonium acetate, and minor amounts of impurities.

3. The method of preparing of claim 2, wherein the insulin detention chromatography collection comprises one or more features selected from the group consisting of:

(a) The concentration of the Degu insulin is 0.5-15 mg/mL, preferably 2-10 mg/mL;

(b) The volume fraction of acetonitrile is 10% -40%, preferably 25% -35%.

4. The method of claim 1, wherein the crystallization fluid comprises one or more characteristics selected from the group consisting of:

(a) The phenolic substance is selected from the group consisting of: phenol, o-cresol, m-cresol, p-cresol, m-ethylphenol, or combinations thereof, preferably phenol;

(b) The salt substance is selected from the following group: sodium chloride, potassium chloride, ammonium acetate, sodium acetate, ammonium citrate, sodium citrate, or a combination thereof, preferably sodium chloride;

(c) The zinc salt is selected from the group consisting of: zinc chloride, zinc bromide, zinc iodide, zinc acetate, zinc oxide, zinc sulfate, or a combination thereof, preferably an inorganic zinc salt, more preferably zinc chloride;

(d) The pH regulator is an alkaline regulator, wherein the alkaline regulator is selected from sodium hydroxide, potassium hydroxide and ammonia water, and preferably sodium hydroxide.

5. The method of any one of claims 1-4, wherein the crystallization liquid comprises one or more characteristics selected from the group consisting of:

(a) The concentration of the insulin diglucoside in the crystallization liquid is 2-8 g/L;

(b) The volume fraction of acetonitrile in the crystallization liquid is 10% -20%;

(c) The phenolic substance accounts for 0.05-1.0% of the mass and volume fraction of the crystallization liquid;

(d) The concentration of the salt substance in the crystallization liquid is 0.5-1.5 mol/L;

(e) The molar ratio of the zinc salt to the insulin deluge is (0.5-5): 1;

(f) The pH of the crystallization liquid is 6.6-8.

6. The preparation process according to any one of claims 1 to 4, wherein the crystallization is carried out at 0 to 10 ℃ for 4 to 24 hours, preferably 6 to 20 hours, more preferably 12 to 20 hours.

7. The method of any one of claims 1-4, wherein the method comprises: preparing a crystallization liquid at 15-28 ℃, wherein the crystallization liquid comprises 2-8 g/L of insulin deluge, 0.05-1.0% g/ml of phenolic substances, 0.5-1.5 mol/L of salt substances, 10-20% (ml/ml) of organic solvent, and the molar ratio of zinc salt to insulin deluge (0.5-5): 1, a step of; regulating pH to 6.6-8, cooling to 2-8 deg.c, and crystallizing for 4-24 hr to obtain insulin crystal.

8. The method of any one of claims 1-4, wherein the crystallization liquid comprises one or more characteristics selected from the group consisting of:

(a) The concentration of the insulin diglucoside in the crystallization liquid is 2.5-4 g/L;

(b) The molar ratio of the zinc salt to the insulin deluge is (1-3): 1;

(c) The phenolic substance accounts for 0.05-0.5% of the mass and volume fraction of the crystallization liquid;

(d) The volume fraction of acetonitrile in the crystallization liquid is 10% -15%;

(e) The concentration of the salt substance in the crystallization liquid is 0.8-1.2 mol/L;

(f) The pH of the crystallization liquid is 6.6-7.5.

9. A crystal of insulin deluge, characterized in that it is produced by the method of claim 1, preferably it is a rod-like crystal.

10. The deluge insulin crystal of claim 9, wherein the deluge insulin crystal has one or more characteristics selected from the group consisting of:

(i) The crystals have a burn residue content of less than 5%, preferably less than 3%, more preferably less than 2%;

(ii) The organic solvent residue of the crystals is less than 300ppm, preferably less than 100ppm, more preferably undetected;

(iii) The phenolic residue of the crystals is less than 2000ppm, more preferably less than 1000ppm;

(iv) The length of the rod-like crystal is 10 to 80. Mu.m, more preferably 30 to 40. Mu.m.